Real-World Outcomes of Patients Treated with Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Systematic Review and Meta-Analysis

被引：2
|
作者：
Cheung, Matthew C.
Amitai, Irina
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-140577
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy
    Jones, Jeffrey A.
    Hillmen, Peter
    Coutre, Steven
    Tam, Constantine
    Furman, Richard R.
    Barr, Paul M.
    Schuster, Stephen J.
    Kipps, Thomas J.
    Flinn, Ian W.
    Jaeger, Ulrich
    Burger, Jan A.
    Cheng, Mei
    Lee, Dana
    James, Danelle F.
    Byrd, John C.
    O'Brien, Susan
    BLOOD, 2014, 124 (21)
  • [42] Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence
    Molica, Stefano
    Scalzulli, Potito Rosario
    Scarfo, Lydia
    Guarini, Attilio
    Murru, Roberta
    Sportoletti, Paolo
    Frigeri, Ferdinando
    Albano, Francesco
    Di Renzo, Nicola
    Sanna, Alessandro
    Innocenti, Idanna
    Massaia, Massimo
    Coscia, Marta
    Pennese, Elsa
    Patti, Caterina
    Reda, Gianluigi
    Tafuri, Agostino
    Regazzoni, Giulia
    Di Candia, Michele
    Mauro, Francesca Romana
    BLOOD, 2022, 140 : 4178 - 4180
  • [43] Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study
    Mauro, Francesca Romana
    Scalzulli, Potito Rosario
    Scarfo, Lydia
    Minoia, Carla
    Murru, Roberta
    Sportoletti, Paolo
    Frigeri, Ferdinando
    Albano, Francesco
    Di Renzo, Nicola
    Sanna, Alessandro
    Laurenti, Luca
    Massaia, Massimo
    Cassin, Ramona
    Coscia, Marta
    Patti, Caterina
    Pennese, Elsa
    Tafuri, Agostino
    Chiarenza, Annalisa
    Galieni, Piero
    Perbellini, Omar
    Selleri, Carmine
    Califano, Catello
    Ferrara, Felicetto
    Cuneo, Antonio
    Murineddu, Marco
    Palumbo, Gaetano
    Scortechini, Ilaria
    Tedeschi, Alessandra
    Trentin, Livio
    Varettoni, Marzia
    Pane, Fabrizio
    Liberati, Anna Marina
    Merli, Francesco
    Morello, Lucia
    Musuraca, Gerardo
    Tani, Monica
    Ibatici, Adalberto
    Regazzoni, Giulia
    Di Candia, Michele
    Palma, Maria
    Arienti, Danilo
    Molica, Stefano
    CANCERS, 2024, 16 (06)
  • [44] Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Lei, Matthew M.
    Sorial, Mark N.
    Lou, Uvette
    Yu, Michelle
    Medrano, Andrea
    Ford, Josie
    Nemec, Ronald A.
    Abramson, Jeremy S.
    Soumerai, Jacob D.
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 653 - 659
  • [45] Real-world healthcare resource utilization (HRU)/costs associated with venetoclax treatment among chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients.
    Rogers, Kerry Anne
    Emond, Bruno
    Manceur, Ameur M.
    Kinkead, Frederic
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices
    Hou, Jing-Zhou
    Blanc, Simon
    Maglinte, Gregory A.
    Vasudevan, Anupama
    Rui, Anna
    Gart, Mike
    Pham, Hoa
    Aton, Lindsay
    Wang, Brandon
    Choksi, Rushir J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] CHLORAMBUCIL FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - SYSTEMATIC REVIEW AND META-ANALYSIS
    Vidal, L.
    Gurion, R.
    Gafter-Gvili, A.
    Raanani, P.
    Bairy, O.
    Robak, T.
    Shpilberg, O.
    HAEMATOLOGICA, 2012, 97 : 57 - 57
  • [48] IDELALISIB IN COMBINATION WITH RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): REAL-WORLD EXPERIENCE THROUGH AN EARLY ACCESS PROGRAM IN EUROPE AND AUSTRALIA
    Li, J. J.
    Yong, A. S.
    Justicia, J. L.
    Smith, C.
    Delgado, J.
    HAEMATOLOGICA, 2016, 101 : 229 - 229
  • [49] Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
    Gilles Salles
    Emmanuel Bachy
    Lukas Smolej
    Martin Simkovic
    Lucile Baseggio
    Anna Panovska
    Hervé Besson
    Nollaig Healy
    Jamie Garside
    Wafae Iraqi
    Joris Diels
    Corinna Pick-Lauer
    Martin Spacek
    Renata Urbanova
    Daniel Lysak
    Ruben Hermans
    Jessica Lundbom
    Evelyne Callet-Bauchu
    Michael Doubek
    Annals of Hematology, 2019, 98 : 2749 - 2760
  • [50] Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia
    Muluneh, Benyam
    Coombs, Catherine
    Drawdy, Lauren
    Kline, Theresa
    Deal, Allison
    Zhu, Anqi
    Miller, Jordan
    Sketch, Margo
    LEUKEMIA & LYMPHOMA, 2020, 61 : 119 - 119
12345